Orelabrutinib

Research use only, not for human use.

Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).

Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). (In Vitro):With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors.(In Vivo):Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.

With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors.

Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.

ICP-022

Tyrosine Kinase

BTK

BTK

——

——

1655504-04-3

427.5

C26H25N3O3

>98% (HPLC)

DMSO:250 mg/mL (584.80 mM; Need ultrasonic)

NC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)C(=O)C=C

——

(-20℃)

With Ice Pack

≥ 2 years